MIVetsCan: Cannabidiol (CBD)-Care Trial

Eligibility Criteria

• * Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
• * Armed Services Veteran
• * Reports moderate to severe chronic pain defined by protocol
• * Currently using or interested in using cannabis for pain management
• * Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention
• * Individuals of reproductive potential must agree to use acceptable birth control per protocol
• * Participants must also agree not to donate sperm or eggs during study drug administration
• * Willingness to attend all study visits (may be done virtually)
• * Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
• * Willingness to wear Fitbit or other similar sensor for passive-data collection
• * Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use
• * Not an Armed Services Veteran (or dishonorable discharge status)
• * Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
• * Participant reports pregnancy or are nursing
• * Planning to move out of a state with legal recreational marijuana use during course of study
• * Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol
• * Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
• * Participation in any other clinical trials over the course of this study
• * Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
• * Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)
• * Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures
• * Current diagnosis of cancer
• * Current valproate and clobazam use per self-report or medical records
• * Self-reported allergies to sesame oil or cannabis/cannabinoids